Therabest Japan Inc. started its research activities at Creative Lab Kobe
(Minatojima-minamimachi, Chuo-ku, Kobe city) as of June, 2022. Therabest
Japan, a subsidiary of South Korea’s THERABEST specializing in iPSC-derived
immune cell therapy, was established in February, 2022. Therabest Japan will
develop safe, efficient, and scalable off-the-shelf allogeneic cell therapy and
provide more patients with access to effective medical care. Therabest Japan
will implement the expansion of iPSC application technologies as well as joint
researches and partnerships with other companies and universities.